Sales slide for krill player amid plant expansion

By staff reporter

- Last updated on GMT

Related tags: Clinical trial, Pharmacology

Leading krill player, Neptune Technologies & Bioressources, has seen sales slip by eight per cent to $2.88 million, from $3.13m in Q1 in 2008, but has put in place plant expansion and continued with acquisitions.

The Canadian company recorded a net loss of $1.41m compared to $1.28m over the same period of comparison, as expansion costs were factored into the equation, but turned in a positive earnings before interest, tax, depreciation, amortization (EBITDA) of $36,000.

The company said results were affected by the temporary closure of its Quebec plant as equipment upgrades were put in place and other facilities tweaked. This work being completed, Neptune’s capacity for krill-sourced ingredients is up to 90,000kg per annum.

Corporate expansion meant EBITDA dropped to $284,000 after research and development work carried out at sub-divisions, Acasti Pharma and NeuroBioPharm, drew funding from the parent over the three-month period ended May 31.

Neptune said Acasti has completed work toward an IND and completed animal pharmacology and toxicology studies, pharmacokinetics, mechanism of action, GMP chemistry, manufacturing, control data and proposed clinical protocols information.

A clinical trial application in Canada was underway.

Krill are tiny shrimp gaining attention as a rich source of omega-3, as well as other nutrients.

There are about 85 species of the deepwater marine planktonic crustacean, or deepwater shrimp, which the planet's most abundant animal biomass and which when captured and converted to oil, pack 48 times the antioxidant punch of standard fish oils, according to ORAC antioxidant scales.

Neptune’s products are available in North America, Europe, Asia and Australia.

Related news

Show more

Related products

show more

DHA ORIGINS™: The sustainable potential of algae.

DHA ORIGINS™: The sustainable potential of algae.

Fermentalg | 22-Jun-2020 | Technical / White Paper

Consumers find out about nutritional quality by closely scrutinizing the labeling and list of ingredients (clean label). They are interested in the provenance...

Optimal Cardiovascular Health Requires Vitamin K2

Optimal Cardiovascular Health Requires Vitamin K2

NattoPharma USA, Inc. | 15-Jun-2020 | Technical / White Paper

In these trying times, general health and basic nutrition are more important than ever. New research now punctuates the importance of securing this healthy...

Learn About dicentra’s Clinical Trial Services

Learn About dicentra’s Clinical Trial Services

dicentra – CRO and regulatory consulting firm | 10-Jun-2020 | Product Brochure

Learn about our people, our location, and our technology to discover why dicentra CRO is the best choice for your next research needs.

Natreon Immunity White Paper

Natreon Immunity White Paper

Natreon Inc. | 09-Jun-2020 | Technical / White Paper

Read through Natreon’s White Paper on Immunity Support to learn more about how Ayurvedic ingredients, Sensoril® Ashwagandha, Capros® Amla, and PrimaVie®...

Related suppliers

Follow us


View more